Evidence map›Paper›PMID 35198235›Full record

ArticleJournal of virus eradication2022

Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice.

Farihah Malik, Vladimir Chulanov, Nikolay Pimenov, Anastasia Fomicheva, Rebecca Lundin, Nataliia Levina, Claire Thorne, Anna Turkova, Giuseppe Indolfi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virus eradication, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Farihah MalikUCL Great Ormond Street Institute of Child Health, University College London, London, UK.
Vladimir ChulanovNational Medical Research Center of Tuberculosis and Infectious Diseases, Moscow, Russia.
Nikolay PimenovNational Medical Research Center of Tuberculosis and Infectious Diseases, Moscow, Russia.
Anastasia FomichevaNational Medical Research Center of Tuberculosis and Infectious Diseases, Moscow, Russia.
Rebecca LundinInstitute for Maternal and Child Health, IRCCS "Burlo Garafolo", Trieste, Italy.
Nataliia LevinaFondazione Penta Onlus, Padova, Italy.
Claire ThorneUCL Great Ormond Street Institute of Child Health, University College London, London, UK.
Anna TurkovaMRC Clinical Trials Unit at University College London, London, UK.
Giuseppe IndolfiDepartment Neurofarba, University of Florence and Meyer Children's University-Hospital, Florence, Italy.
Central Scientific Research Institute of Tuberculosis Russian Academy of Medical Sciences · RUUniversity College London · GBIRCCS Materno Infantile Burlo Garofolo · ITMeyer Children's Hospital · ITMRC Clinical Trials Unit at UCL · GBPENTA Foundation · ITSechenov University · RU

Funding

Medical Research Council MC_UU_00004/03
6 · The paper itself

Abstract

backgroundThe Russian Federation has the largest paediatric hepatitis C virus (HCV) disease burden in the World Health Organization European region with an estimated 118,000 children living with HCV viraemia. Direct-acting antivirals (DAAs) have been available for adults in Russia since 2015 and approved for treatment of adolescents aged ≥12 years since 2019. We evaluated DAA availability and uptake for HCV treatment of children and adolescents and clinical practices on diagnosis and management of paediatric HCV in Russia.

methodsA survey was distributed to regional ministries of health in 85 administrative regions during September 2020. The survey consisted of 22 items collecting data on: type of facility, aggregate patient characteristics, HCV testing practices for children and pregnant women and HCV management and treatment practices for children.

resultsSurvey responses were received from 37 of the 85 regions in Russia (response rate 44%). 2159 children and adolescents with chronic HCV were in follow-up; 1089 (50%) were female. Of 2080 children with available data on age-groups, 134 (6%) were <3 years, 336 (16%) 3-<6 years, 718 (35%) 6-<12 years and 892 (43%) 12-<18 years. 134 (15%) of 892 adolescents ≥12 years received DAAs, 96 (72%) glecaprevir/pibrentasvir, 26 (19%) sofosbuvir, 8 (6%) daclatasvir and 4 (3%) sofosbuvir/ledipasvir.

conclusionsThis study provides a baseline of DAA uptake in early stages of rollout for children and adolescents. The use of DAAs for treatment of adolescents in Russia presents a unique opportunity for HCV micro-elimination in this population.

Indexed as

Direct acting antiviralsHepatitis CMonitoringPaediatricPolicies

Identifiers

PMID35198235
PMCPMC8844707
OpenAlexW4210776943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.